U.S. Markets open in 8 hrs 22 mins

ARCA biopharma, Inc. (ABIO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.4600-0.0400 (-1.60%)
At close: 04:00PM EDT
2.3900 -0.07 (-2.85%)
After hours: 07:54PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close2.5000
Bid0.0000 x 800
Ask0.0000 x 800
Day's Range2.4400 - 2.5300
52 Week Range1.7100 - 3.8400
Avg. Volume119,659
Market Cap35.449M
Beta (5Y Monthly)2.40
PE Ratio (TTM)N/A
EPS (TTM)-1.4850
Earnings DateMar 16, 2022 - Mar 21, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Jacob Ma-Weaver Joins ARCA biopharma Board of Directors

    WESTMINSTER, Colo., June 21, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO) today announced that Jacob Ma-Weaver has joined its Board of Directors. “We are pleased to welcome Jacob Ma-Weaver, the managing member of ARCA’s largest shareholder, to our Board,” said Robert E. Conway, Chairman of ARCA’s Board of Directors. “We appreciate his participation and input as we explore and evaluate strategic options for maximizing stockholder value.” Mr. Ma-Weaver is the Managing Member of Cab

  • GlobeNewswire

    ARCA biopharma Retains Ladenburg Thalmann to Support Strategic Options Review

    WESTMINSTER, Colo., May 05, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO) today announced that it has retained Ladenburg Thalmann & Co. Inc. to act as its financial advisor. In April 2022, the Board of Directors established a Special Committee to explore and evaluate strategic options for maximizing stockholder value. Potential strategic alternatives that may be explored or evaluated as part of this process include the potential for an acquisition, merger, business combination or

  • GlobeNewswire

    ARCA biopharma Announces First Quarter 2022 Financial Results

    Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options WESTMINSTER, Colo., May 02, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported first quarter 2022 financial results and provided a corporate update. Dr. Michael Bristow, ARCA’s Pres